2124-P: Burden of Diabetic Ketoacidosis among Youth with Diabetes: A Hospital Claims Analysis

Introduction and Objective: Diabetic ketoacidosis (DKA) is a serious complication of diabetes. Herein, we sought to assess DKA-related hospitalizations in children with either type 1 (T1D) or type 2 diabetes (T2D), stratified by whether a DKA diagnosis code was primary or secondary, and estimate differences in mortality, and cost of hospitalizations. Methods: We searched the 2022 Kids’ Inpatient Database (KID) for children (18yrs) with T1D (E10. xx any position) or T2D (E11. xx, any position) and DKA hospitalizations using ICD-10 codes (E10. 1, E10. 10, E10. 11, E11. 1, E11. 10, E11. 11 as the primary or secondary diagnostic code). After adjusting to national estimates, we reported incidence, length of stay (LOS), mortality, and hospitalization costs. Results: In 2022, among 38, 874 pediatric hospitalizations in youth with T1D or T2D, 23, 983 (59. 1%) hospitalizations were associated with a DKA diagnosis code T1D, N = 22, 577 (58. 1%) ; T2D, N = 1, 406 (3. 6%). The majority of youth admitted for DKA were covered by Medicaid (TABLE). There were 49 deaths associated with DKA hospitalizations, LOS ranged from 2. 4 to 7. 3 days, and costs ranged from 9, 461 to 38, 074. Conclusion: DKA is commonly coded during hospitalizations of youth with diabetes. While the present analysis could not address if DKA occurred at disease onset, our findings highlight the substantial burden of DKA in terms of incidence, cost, and duration of admission. Disclosure J. Sherr: Other - research support, consultant, advisory board member; Current; Abbott Diabetes. Other - advisory board member, consultant; Current; Vertex Pharmaceuticals Incorporated. Consultant; Current; Ypsomed AG. Research Support; Current; Dexcom, Inc. , JDRF, Provention Bio, Inc. , National Institutes of Health. Other - research support, consultant, advisory board member; Current; Insulet Corporation, Medtronic. Research Support; Current; Sanofi. Advisory Panel; Current; sequel med tech. N. Virdi: Employee; Current; Abbott Diabetes. A. Lee: Employee; Current; Abbott Diabetes. Y. Poon: Employee; Current; Abbott Diabetes. Stock/Shareholder; Current; Abbott Diabetes. Funding Abbott Diabetes Care